dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
Published 5 years ago • 638 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:32
dr. bradley on next steps for research in nonmetastatic prostate cancer
-
9:00
differences between ar-targeted therapy in prostate cancer
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
0:14
copy of dr. bradley on exercise in treatment-related ae management
-
7:00
case 1: differences in ar-targeted therapy adverse events in nmcrpc
-
1:48
dr. bradley on impact of spartan and prosper in nonmetastatic crpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:47
dr. hussain on potential of enzalutamide in prostate cancer
-
0:18
the #innovate trial is for patients with node-positive #prostatecancer.
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
6:42
titan trial
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
3:28
apalutamide and the titan clinical trial
-
3:06
titan trial
-
9:51
overall survival data presented at asco 2020 for nmcrpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
12:42
pca commentary - nmcrpc and androgen receptor inhibition: enzalutamide, apalutamide and darolutamide
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
1:47
dr. saad on apalutamide combination for castration-resistant prostate cancer